Pathogenesis of indoor fungal diseases

Medical Mycology

Volumn 42, Issue 2, 2004, Pages 107-117

  McGinnis, Michael R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,8 DIHYDROXYNAPHTHALENE MELANIN; BETA 1,3 GLUCAN; HEMOLYSIN; HYDROPHOBIN; MELANIN; MYCOTOXIN; STACHYLYSIN; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ALLERGIC DISEASE; CELL WALL; FUNGAL CELL; HEALTH HAZARD; INTOXICATION; MOULD; MYCOSIS; NONHUMAN; PATHOGENESIS; REVIEW;

AIR MICROBIOLOGY; AIR POLLUTION, INDOOR; HUMANS; MYCOSES; MYCOTOXINS; STACHYBOTRYS;

EID: 1842830698     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001661473     Document Type: Review

References (115)

1. Cleary JA, Kelly GE, Husband AJ. The effect of molecular weight and beta-1,6-linkages on priming of macrophage function in mice by (1,3)-beta-D-glucan. Immunol Cell Biol 1999; 77: 395-403.
2. Falch BH, Espevik T, Ryan L, et al. The cytokine stimulating activity of (1 → 3)-beta-D-glucans is dependent on the triple helix conformation. Carbohydr Res 2000; 329: 587-596.
3. Brown GD, Taylor PR, Reid DM, et al. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002; 196: 407-412.
4. Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-1371.
5. Svirshchevskaya EF, Kurup VP. Immunotherapy of allergic bronchopulmonary aspergillosis: A clinical and experimental approach. Front Biosci 2003; 8: s92-s101.
6. Wan GH, Li CS, Guo, SP, et al. An airborne mold-derived product, beta-1,3-D-glucan, potentates airway allergic responses. Eur J Immunol 1999; 29: 2491-2497.
7. Suzuki Y, Adachi Y, Ohno N, et al. Th1/Th2-Balancing immunomodulating activity of gel-forming (1,3)-beta-glucans from fungi. Biol Pharm Bull 2001; 24: 811-819.
8. Kougias P, Wei D, Rice PJ, et al. Normal human fibroblasts express pattern recognition receptors for fungal (1 → 3 -β-D-glucans. Infect Immun 2001; 69: 3933-3938.
9. Miller DK, Alwis EU, Fisette L, et al. Enzyme-linked immunosorbent assay specific for (1 → 6) branched, (1 → 3 -β-D-glucan detection in environmental samples. Appl Environ Microbiol 2001; 67: 5420-542.
10. Wessels JGH. Hydrophobins: Proteins that change the nature of the fungal surface. Adv Microb Physiol 1997; 38: 1-45.
11. Wosten HA, Schuren FH, Wessels JG. Interfacial self-assembly of a hydrophobin into an amphipathic protein membrane mediates fungal attachment to hydrophobic surfaces. EMBO J 1994; 13: 5848-5854.
12. Paris S, Debeaupuis JP, Crameri R, et al. Conidial Hydrophobins of Aspergillus fumigatus. Appl Environ Microbiol 2003; 69: 1581-1588.
13. Weichel M, Schmid-Grendelmeier P, Rhyner C, et al. Immunoglobulin E-binding and skin test reactivity to hydrophobin HCh-1 from Cladosporium herbarium, the first allergenic cell wall component of fungi. Clin Exp Allergy 2003; 33: 72-77.
14. Wheeler MH, Bell AA. Melanins and their importance in pathogenic fungi. Curr Top Med Mycol 1988; 2: 338-387.
15. Butler MJ, Day AW. Fungal melanins: A review. Can J Microbiol 1998; 44: 1115-1136.
16. Jacobson ES. Pathogenic roles for fungal melanins. Clin Microbiol Rev 2000; 13: 708-717.
17. Langfelder K, Streibel M, Jahn B, et al. Biosynthesis of fungal melanins and their importance for human pathogenic fungi. Fungal Genet Biol 2003; 38: 143-158.
18. Larsen TO. Volatiles in fungal taxonomy. In: Frisvad JC, Bridge PD, Arora DK (eds). Chemical Fungal Taxonomy. New York: Marcel Dekker, 1998: 263-287.
19. Pohland AE. Mycotoxins in review. Food Addit Contamin 1993; 10: 17-28.
20. Kaminski E, Stawicki S, Wasowicz E. Volatile flavor compounds produced by molds of Aspergillus, Penicillium, and Fungi Imperfecti. Appl Microbiol 1974; 27: 1001-1004.
21. Medsker JA, Jenkins LD, Thomas JF, et al. Odorous compounds in natural waters. 2-exo-hydroxy-2-methyl-boran, the major compound produced by several actinomycetes. Environ Sci Technol 1969; 3: 476-477.
22. Haw KM, Connell DW, Richardson BJ. Quantitative structure-activity relationships for nasal pungency thresholds of volatile organic compounds. Toxicol Sci 1999; 47: 93-98.
23. Otto D, Molhave L, Rose G, et al. Neurobehavioral and sensory irritant effects of controlled exposure to a complex mixture of volatile organic compounds. Neurotoxicol Teratol 1990; 12: 649-652.
24. Ammann HM. Is indoor mold contamination a threat to health? (2001) Available at http://www.doh.wa.gov/ehp/oechas/mold.html.
25. Miller JD, LaFlamme AM, Sobol Y, et al. Fungi and fungal products in some Canadian homes. Inter Biodeterior 1988; 24: 103-120.
26. Wilkins K. Volatile sesquiterpenes from Stachybotrys chartarum: Indicators for trichothecene producing mold species? Environ Sci Pollut Res 2000; 7: 77-78.
27. Jelen HH, Mirocha CJ, Wasowicz E, et al. Production of volatile sesquiterpenes by Fusarium sambucinum strains with different abilities to synthesize trichothecenes. Appl Environ Microbiol 1995; 61: 3815-3820.
28. Fischer G, Dott W. Relevance of airborne fungi and their secondary metabolites for environmental, occupational and indoor hygiene. Arch Microbiol 2003; 179: 75-82.
29. 1 adducts to serum albumin. Scand J Work Environ Health 1991; 17: 436-440.
30. Nikulin M, Reijula K, Jarvis BB, et al. Effects of intranasal exposure to spores of Stachybotrys atra in mice. Fundam Appl Toxicol 1997; 35: 182-188.
31. Pang VF, Lambert RJ, Felsburg PJ, et al. Experimental T-2 toxicosis in swine following inhalation exposure: clinical signs and effects on hematology, serum biochemistry, and immune response. Fundam Appl Toxicol 1988; 11: 100-109.
32. Nikulin M, Reijula K, Jarvis BB, et al. Experimental lung mycotoxicosis in mice induced by Stachybotrys atra. Int J Exp Pathol 1996; 77: 213-218.
33. 3H]T-2 toxin adsorbed from corn dust. Fed Chem Toxicol 1984; 22: 893-896.
34. American College of Occupational and Environmental Medicine (2003) Available at: http://www.acoem.org/guidelines/article.asp?ID=52
35. Nielsen KF. Mycotoxin production by indoor molds. Fungal Genet Biol 2003; 39: 103-117.
36. Nielsen KF. Mold growth on building materials. Secondary metabolites, mycotoxins and biomarkers. Biocentrum-DTU, Technical University of Denmark, Lyngby, Denmark (2001) Available at: http://www.biocentrum.dtu.dk/mycology/publications/phd-kfn.pdf
37. Alexander NJ, McCormick SP, Hohn TM. TRI12, a trichothecene efflux pump from Fusarium sporotrichioides: gene isolation and expression in yeast. Mol Gen Genet 1999; 261: 977-984.
38. Wuchiyama J, Kimura M, Yamaguchi I. A trichothecene efflux pump encoded by Tri102 in the biosynthetic gene cluster of Fusarium graminearum. J Antibiot 2000; 53: 196-200.
39. Weidenborner M. Encyclopedia of Food Mycotoxins. Heidelberg: Springer Verlag, 2001.
40. Miller JD, Rand TG, Jarvis BB. Stachybotrys chartarum: cause of human disease or media darling? Med Mycol 2003; 41: 271-292.
41. Tuomi T, Reijula K, Johnsson T, et al. Mycotoxins in crude building materials from water-damaged buildings. Appl Environ Microbiol 2000; 66: 1899-1904.
42. Jarvis BB. Chemistry and toxicology of molds isolated from water-damaged buildings. Adv Exp Med Biol 2002; 504: 43-52.
43. Ominski KH, Marquardt RR, Sinha RN, et al. Ecological aspects of growth and mycotoxin production by storage fungi. In: Miller JD, Trehohn HL (eds). Mycotoxins in Grain. Compounds other than Aflatoxin. St Paul, MN: Eagan Press, 1997: 287-312.
44. Velluti A, Marin S, Bettucci L, Ramos AJ, et al. The effect of fungal competition on colonization of maize grain by Fusarium moniliforme, F. proliferatum and F. graminearum and on fumonisin B1 and zearalenone formation. Int J Food Microbiol 2000; 59: 59-66.
45. Richard JL, Plattner RD, May J, et al. The occurrence of ochratoxin A in dust collected from a problem household. Mycopathologia 1999; 146: 99-103.
46. Hughes DM, Gahl MJ, Graham CH, et al. Overt signs of toxicity to dogs and cats of dietary deoxynivalenol. J Anim Sci 1999; 77: 693-700.
47. Lutsky I, Mor N, Yagen B, et al. The role of T-2 toxin in experimental alimentary toxic aleukia: A toxicity study in cats. Tox Appl Pharmacol 1978; 43: 111-124.
48. Richard JL, Payne GA, Desjardins AE, et al. Mycotoxins. Risks in plant, animal, and human systems. CAST Task Force Report 139, 2003.
49. Liu DK, Wannemacher RW, Snider TH, et al. Efficacy of the topical skin protectant in advanced development. Clin Lab Med 2001; 21: 593-605.
50. Croft WA, Jastromski BM, Croft AL, et al. Clinical confirmation of trichothecene mycotoxicosis in patient urine. J Environ Biol 2002; 23: 301-320.
51. Thuvander A, Paulsen JE, Axberg K, et al. Levels of ochratoxin A in blood from Norwegian and Swedish blood donors and their possible correlation with food consumption. Food Chem Toxicol 2001; 39: 1145-1151.
52. Ozcelik N, Kosar A, Soysal D. Ochratoxin A in human serum samples collected in Isparta-Turkey from healthy individuals and individuals suffering from different urinary disorders. Toxicol Lett 2001; 121: 9-13.
53. Sepcic K, Berne S, Potrich C, et al. Interaction of ostreolysin, a cytolytic protein from the edible mushroom Pleurotus ostreatus, with lipid membranes and modulation by lysophospholipids. Eur J Biochem 2003; 270: 1199-1210.
54. Wang M, Trigueros V, Paquereau L, et al. Proteins as active compounds involved in insecticidal activity of mushroom fruiting bodies. J Econ Entomol 2002; 95: 603-607.
55. Berne S, Krizaj I, Pohleven F, et al. Pleurotus and Agrocybe hemolysins, new proteins hypothetically involved in fungal fruiting. Biochim Biophys Acta 2002; 1570: 153-159.
56. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 2001; 39: 2971-2974.
57. Vesper SJ, Magnuson ML, Dearborn DG, et al. Initial characterization of the hemolysin stachylysin from Stachybotrys chartarum. Infect Immun 2001; 69: 912-916.
58. Vesper SJ, Vesper MJ. Stachylysin may be a cause of hemorrhaging in humans exposed to Stachybotrys chartarum. Infect Immun 2002; 70: 2065-2069.
59. Gregory L, Rand TG, Dearborn D, et al. Immunocytochemical localization of stachylysin in Stachybotrys chartarum spores and spore-impacted mouse and rat lung tissue. Mycopathologia 2002; 156: 109-117.
60. Rand TG, White K, Logan A, et al. Histological, immunohistochemical and morphometric changes in lung tissue in juvenile mice experimentally exposed to Stachybotrys chartarum spores. Mycopathologia 2003; 156: 119-131.
61. Esch RE. Selection of antigens for skin testing. Immunol Allergy Clin North Am 2001; 21: 251-261.
62. Esch RE, Hartsell CJ, Crenshaw R, et al. Common allergenic pollens, fungi, animals, and arthropods. Clin Rev Allergy Immunol 2001; 21: 261-292.
63. Bhatnagar D, Yu J, Ehrlich KC. Toxins of filamentous fungi. Chem Immunol 2002; 81: 167-206.
64. Bondy GS, Pestka JJ. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev 2000; 3: 109-143.
65. Faergemann J. Atopic dermatitis and fungi. Clin Microbiol Rev 2002; 15: 545-563.
66. Leung DY, Boguniewicz M. Advances in allergic skin diseases. J Allergy Clin Immunol 2003; 111(Suppl. 3): S805-S812.
67. Gerberick GF, Cruse LW, Ryan CA, et al. Use of a B cell marker (B220) to discriminate between allergens and irritants in the local lymph node assay. Toxicol Sci 2002; 68: 420-428.
68. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nceh/airpollution/mold/AIPHIcasedef.htm
69. Stewart S, Fawcett J, Jacobson. Interstitial haemosiderin in the lungs of sudden infant death syndrome: A histological hallmark of 'near-miss' episodes? J Pathol 1985; 145: 53-58.
70. Chazalet V, Debeaupuis JP, Sarfati J, et al. Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. J Clin Microbiol 1998; 36: 1494-1500.
71. Neuveglise C, Sarfati J, Debeaupuis J P, et al. Longitudinal study of Aspergillus fumigatus strains isolated from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis; 16 1997; 1997: 747-750.
72. Taylor JW, Geiser DM, Burt A, et al. The evolutionary biology and population genetics underlying fungal strain typing. Clin Microbiol Rev 1999; 12: 126-146.
73. Brenier-Pinchart MP, Lebeau B, Devouassoux G, et al. Aspergillus and lung transplant recipients: A mycologic and molecular epidemiologic study. J Heart Lung Transplant 1998; 17: 972-979.
74. Soll DR. The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 2000; 13: 332-370.
75. Sudakin DL. Dietary aflatoxin exposure and chemoprevention of cancer: A clinical review. J Toxicol Clin Toxicol 2003; 41: 195-204.
76. Shin EJ, Guertler N, Kim E, et al. Screening of middle ear effusion for the common sinus pathogen Bipolaris. Eur Arch Otorhinolaryngol 2003; 260: 78-80.
77. Ferrer C, Montero J, Alio JL, et al. Rapid molecular diagnosis of posttraumatic keratitis and endophthalmitis caused by Alternaria infectoria. J Clin Microbiol 2003; 41: 3358-3360.
78. Kawazu M, Kanda Y, Goyama S, et al. Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Am J Hematol 2003; 72: 27-30.
79. O'Shaughnessy EM, Shea YM, Witebsky FG. Laboratory diagnosis of invasive mycoses. Infect Dis Clin North Am 2003; 17: 135-158.
80. Apostolakos MJ, Rossmoore H, Beckett WS. Hypersensitivity pneumonitis from ordinary residential exposures. Environ Health Perspect 2001; 109: 979-981.
81. Hogan MB, Patterson R, Pore RS, et al. Basement shower hypersensitivity pneumonitis secondary to Epicoccum nigrum. Chest 1996; 110: 854-856.
82. Stone CA, Johnson GC, Thornton JD, et al. Leucogyrophana pinastri, a wood decay fungus as a probable cause of an extrinsic allergic alveolitis syndrome. Aust NZ J Med 1989; 19: 727-729.
83. Dill I, Trautmann C, Szewzyk R. Mass development of Stachybotrys chartarum on decomposable plant-pots made of recycling paper. Mycoses 1997; 40(Suppl. 1): 110-114.
84. Snijders CH, Samson RA, Hoekstra ES, et al. Analysis of Fusarium causing dermal toxicosis in marram grass planters. Mycopathologia 1996; 135: 119-28.
85. Bamburg JR, Marsas WF, Riggs NV, et al. Toxic spiroepoxy compounds from fusaria and other hyphomycetes. Biotech Bioeng 1968; 10: 445-455.
86. Bamburg JR, Strong FM. 12,13-Epoxytrichothecenes. In: Kadis S, Ciegler A, Ali SJ (eds). Microbial Toxins, vol. 7. New York: Academic Press, 1971: 207-292.
87. Adler SS, Lowenbraun S, Birch B, et al. Anguidine: a broad phase II study of the Southeastern Cancer Study Group. Cancer Treat Rep 1984; 68: 423-425.
88. Belt RJ, Haas CD, Joseph U, et al. Phase I study of anguidine administered weekly. Cancer Treat Rep 1979; 63: 1993-1995.
89. Bukowski R, Vaughn C, Bottomley R, et al. Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 381-383.
90. DeSimone PA, Greco FA, Lessner HF, et al. Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial. Am J Clin Oncol 1986; 9: 187-188.
91. Heyndrickx A, Sookvanichsilp N, Van den Heede M. Detection of trichothecene mycotoxins (yellow rain) in blood, urine and faeces of Iranian soldiers treated as victims of a gas attack. Arch Belg 1984; Suppl.: 143-146.
92. Heyndrickx A, Heyndrickx B. Treatment of Iranian soldiers attacked by chemical and microbiological war gases. Arch Belg 1984; Suppl.: 57-59.
93. Mirocha C, Pawlosky RJ, Chatterjee K. Analysis for Fusarium toxins in various samples implicated in biological warfare in Southeast Asia. J Assoc Office Anal Chem 1983; 66: 1485-1499.
94. Rosen RT, Rosen JD. Presence of four Fusarium mycotoxins and synthetic material in 'yellow rain'. Evidence for the use of chemical weapons in Laos. Biomed Mass Spectrom 1982; 9: 443-450.
95. Spyker MS, Spyker DA. Yellow rain: Chemical warfare in Southeast Asia and Afghanistan. Vet Hum Toxicol 1983; 25: 335-340.
96. Watson SA, Mirocha CJ, Hayes AW. Analysis for trichothecenes in samples from Southeast Asia associated with 'Yellow Rain'. Fundam Appl Toxicol 1984; 4: 700-717.
97. Andersen B, Nielsen KF, Jarvis BB. Characterization of Stachybotrys from water-damaged buildings based on morphology, growth, and metabolite production. Mycologia 2002; 94: 392-403.
98. Brian PW, McGowan JC. Biologically active metabolic products of the mold Metarrhizium glutinosum S. Pope. Nature 1946; 157: 334.
99. Brian PW, Hemming HG, Jefferys EG. Production of antibiotics by species of Myrothecium. Mycologia 1948; 40: 363-368.
100. Freeman GC. Further biological properties of trichothecin, an anti-fungal substance from Trichothecium roseum Link, and its derivatives. J Gen Microbiol 1955; 12: 213-221.
101. Forgacs J. Stachybotryotoxicosis. In: Ajl SJ (ed.). Microbial Toxins. New York: Academic Press, 1972: 95-128.
102. Snijders CHA, Samson RA, Hoekstra ES, et al. Analysis of Fusarium causing dermal toxicosis in marram grass planters. Mycopathologia 1996; 135: 119-128.
103. Drobotko VG. Stachybotryotoxicosis a new disease and humans. Am Rev Soviet Med 1945; 2: 238-242.
104. McGovern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol 1999; 135: 311-322.
105. Haig AM Jr. Chemical warfare in Southeast Asia and Afghanistan: Report to Congress from Secretary of State Alexander M. Haig Jr. Special report no. 98. Washington, DC: US Department of State, 1982.
106. Seeley TD, Nowiche JW, Meselson M, et al. Yellow rain. Sci Am 1985; 253: 128-137.
107. Stahl CJ, Green CC, Farnum JB. The incident at Tuol Chrey: Pathological and toxicological examination of a casualty after chemical attack. J Forensic Sci 1985; 30: 317-337.
108. Ember LR. Yellow rain. Chem Eng News 1984; 62: 8-34.
109. Wannemacher RW, Wiener SL. Trichothecene mycotoxins. In: Sidell FR, Takafuji ET, Franz DR (eds). Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, 1997: 655-676.
110. Peraica M, Radic B, Lucic A, et al. Toxic effects of mycotoxins in humans. Bull WHO 1999; 77: 754-766.
111. Murphy WK, Burgess MA, Valdivieso M, et al. Phase I clinical evaluation of anguidine. Cancer Treat Rep 1978; 62: 1479-1502.
112. Yap HY, Murphy WK, DiStefano A, et al. Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep 1979; 63: 789-791.
113. DeSimone PA, Greco FA, Lessner HF. Phase I evaluation of a weekly schedule of anguidine. Cancer Treat Rep 1979; 63: 2015-2017.
114. Bukowski R, Vaughn C, Bottomley R, et al. Phase II study of anguidine in gastrointestinal malignancies: A Southwest Oncology Group Study. Cancer Treat Rep 1982; 66: 381-383.
115. McAfee BJ, Taylor A. A review of the volatile metabolites of fungi found on wood substrates. Nat Toxins 1999; 7: 283-303.